Challenge the expert – Evaluation
Home Case studies Expert interviews eLearning News Expert challenge Treatment options for metastatic urothelial carcinoma: Challenge the expert Evaluation survey Thank you for completing this survey, your feedback helps us create the most relevant independent programs for your learning needs in the future. “*” indicates required fields Name First Last Email Degree How well did […]
Challenge the expert
Home Case studies Expert interviews eLearning News Expert challenge Treatment options for metastatic urothelial carcinoma: Challenge the expert Axel Merseburger, Enrique Grande and María-José Juan-Fita are faced with a challenge to find the best treatment approach for different metastatic urothelial carcinoma (mUC) case studies. They might not agree, but each one will have an opportunity to challenge the other’s […]
Urothelial Cancer eLearning
Home Case studies Expert interviews eLearning News Expert challenge Treatment options for metastatic urothelial carcinoma: eLearning activities Improve your knowledge and confidence in immunotherapy strategies for mUC with this set of three eLearning modules. Expert authors Axel Merseburger, Marc-Oliver Grimm and Simon Chowdhury will cover clinical trial data and real-world evidence to help you support your […]
Evaluation
RETURN HOME Evaluation Help us to design the most relevant educational programs for you. We really appreciate your feedback. How would you rate the overall quality of this treatment map?(Required)1=poor, 10=excellentSelect10987654321 How well did the learning activity fulfil the following objectives?(Required) Select the optimal treatment strategy for patients with ALK or ROS1 mutation positive NSCLC […]
Urothelial Cancer expert interviews
Home Case studies Expert interviews eLearning News Expert challenge Portuguese Translation Treatment options for metastatic urothelial carcinoma: Expert-to-expert interviews Join our leading experts for commentary and debate in three insightful discussion videos. ASCO 22 Annual Meeting Highlights from the ASCO 22 Annual Meeting: an expert discussion with Andrea Apolo and Elizabeth Plimack Andrea Apolo and Elizabeth […]
Digital treatment map for ALK- and ROS1-mutated NSCLC
EVALUATION Thank you for your feedback! × Dismiss alert Welcome to our Digital Treatment Map A practical, expert-led, and evidence-based resource designed to help you navigate the different treatment lines of ALK and ROS1 mutation positive NSCLC. Join Dr Barbara Melosky, Dr Solange Peters, and Dr Ross Camidge as they guide you through this independent […]
Urothelial Cancer news
Home Case studies Expert interviews eLearning News Expert challenge Treatment options for metastatic urothelial carcinoma: News Provided by our news bureau, medwireNews, our conference coverage is a useful resource for healthcare practitioners to keep up to date with the latest medical news. Stay informed on the recent advances and clinical developments presented at key congresses, […]
Urothelial Cancer
Home Case studies Expert interviews eLearning News Expert challenge Portuguese Translation Treatment options for metastatic urothelial carcinoma Urothelial carcinoma is one of the most common malignancies worldwide. This innovative program comprises a suite of educational resources for those managing patients with metastatic urothelial carcinoma (mUC), having a particular focus on the use of immunotherapy strategies. […]
Treatment options for metastatic urothelial carcinoma
Home Case studies Expert interviews eLearning News Expert challenge Portuguese Translation Treatment options for metastatic urothelial carcinoma: Patient case studies Urothelial carcinoma is one of the most common malignancies worldwide. For patients with metastatic urothelial carcinoma (mUC), systemic chemotherapy has been the standard of care for many years but the development of new therapeutics is […]
Clinical Trial Summary Article
At a glance: CDK4/6 inhibitors in advanced breast cancer Cyclin-dependent kinase (CDK)4/6 inhibitors have become an important treatment option for patients with hormone receptor (HR)-positive advanced breast cancer (ABC). Here we outline the key efficacy and safety results reported thus far from the PALOMA, MONALEESA, and MONARCH series of clinical trials of palbociclib, ribociclib, and […]
